Bimatoprost sustained-release - AbbVie
Alternative Names: Bimatoprost implant; Bimatoprost SR; Bimatoprost sustained-release implant; DURYSTALatest Information Update: 09 Jan 2025
At a glance
- Originator Allergan
- Developer AbbVie
- Class Amides; Antiglaucomas; Lipids; Prostaglandins; Small molecules
- Mechanism of Action Prostaglandin F2alpha receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Glaucoma; Ocular hypertension
- Preregistration Submission Withdrawal Open-angle glaucoma
Most Recent Events
- 13 Sep 2024 Preregistration for Ocular hypertension in European Union (Implant) prior to September 2024.
- 13 Sep 2024 Preregistration for Open-angle glaucoma in European Union (Implant) prior to September 2024.
- 13 Sep 2024 Regulatory submission withdrawn for Ocular hypertension in European Union (Implant)